Loading...
Market
Adoption of Novocure's Optune Lua by 50% of US centers for mNSCLC by 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Survey or report from oncology treatment centers or healthcare industry reports
Story
FDA Approves Novocure's Optune Lua for Metastatic NSCLC with PD-1/PD-L1 Inhibitors, Based on LUNAR Study
Oct 15, 2024, 08:09 PM
The FDA has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in treating metastatic non-small cell lung cancer (mNSCLC) for patients who have progressed on or after a platinum-based regimen. This approval, announced on October 15, is based on the LUNAR study, which demonstrated a statistically significant improvement in overall survival (OS). Additionally, sunvozertinib has received Breakthrough Therapy Designation in China for treatment-naive EGFR Exon 20+ non-small cell lung cancer (NSCLC) as of October 14. Furthermore, the FDA has approved durvalumab with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable NSCLC.
View original story
Similar markets
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%